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The morbidity and mortality of adult and pediatric chronic kidney disease (CKD) and 
end-stage renal disease (ESRD) populations are mainly driven by cardiovascular dis-
ease (CVD). Improving CVD outcomes focuses on risk assessment of factors includ-
ing diastolic blood pressure (DBP), systolic blood pressure (SBP), left ventricular mass 
index (LVMI), pulse pressure (PP), and pulse pressure index (PPi), which is calculated as 
PP/SBP. These markers are also proven predictors of CKD progression; however, their 
role in children has not been established. This study aims to evaluate the relationship 
between PP, PPi, ambulatory arterial stiffness index (AASI), and proteinuria with kid-
ney function in pediatric CKD patients; it is a retrospective analysis of 620 patients 
(1-16 years) from the NIDDK Chronic Kidney Disease in Children (CKiD) registry. The 
authors analyzed data for three separate cohorts: an overall CKD as well as immu-
nological versus non-immunological cause for CKD groups. An inverse relationship 
was found between SBP, DBP, and PP with iGFR and LVMI in the overall CKD group. 
Our immunological CKD subgroup showed significantly higher serum creatinine, SBP, 
DBP, and PP values with significantly lower serum albumin levels compared to the 
non-immunological group. There were no significant differences with iohexol-based 
glomerular filtration rate (iGFR), LVMI, PPi, or high-sensitivity C-reactive protein (hs-
CRP) between the two groups. A subgroup analysis demonstrated that SBP, DBP, and 
PP all correlated significantly with LVMI in the immunological CKD patients but not 
the non-immunological subgroup. Additionally, AASI data in the overall CKD popula-
tion were significantly correlated with PP, PPi, and DBP. This study is one of the first 
to correlate noninvasive measurements of vascular compliance including PP, PPi, and 
AASI with iGFR and LVMI in a pediatric CKD cohort. Improving our understanding of 
surrogate markers for early CVD is integral to improving the care of pediatric CKD 
population as these patients have yet to develop the hard end points of ESRD, heart 
failure, myocardial infarction, or stroke.
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1  | INTRODUC TION
Chronic kidney disease (CKD) and end-stage renal disease (ESRD) are 
a significant burden for patients due to their high morbidity and as-
sociated mortality; furthermore, CKD and ESRD care is complex and 
requires a significant portion of our health care resources.1 The mor-
bidity and mortality of adult and pediatric CKD/ESRD populations 
are mainly driven by cardiovascular disease (CVD).2 Hypertension 
(HTN) has long been identified as a paramount independent risk 
factor for CVD development as well as CKD progression; improv-
ing CVD outcomes has focused on risk assessment including anal-
ysis of systolic blood pressure (SBP) and diastolic blood pressure 
(DBP).3 However, as medical management of HTN has improved, the 
onus of care has shifted to prevention including early detection of 
evolving vascular pathology prior to changes in blood pressure, and 
recently, the emphasis has shifted to noninvasive arterial elasticity 
measurements.
The strong prognostic value of arterial stiffness measurements 
has been firmly established over the last two decades in the adult 
CKD and ESRD populations.2 Furthermore, the authors know that 
arterial stiffness measurements offer additive predictive value to 
traditional risk factors with respect to cardiovascular outcomes.2 
However, measurements of arterial stiffness have not been well 
evaluated in the pediatric CKD populations. While well-established 
markers such as pulse wave velocity (PWV) and the augmentation 
index have excellent prognostic value in adults, they are cumber-
some due to the need for specialized equipment and remain mostly 
utilized in research.4,5 Thus, clinicians need arterial stiffness param-
eters that are accessible for routine practice; two such potential 
parameters include pulse pressure (PP) and ambulatory arterial stiff-
ness index (AASI). PP is well established and easily calculated as the 
difference between maximal systolic blood pressure (SBP) and min-
imal diastolic blood pressure (DBP), and increased PP is associated 
with poor CKD outcomes in adults.6 AASI is a newer method and 
is mathematically derived from 24-hour ambulatory blood pressure 
monitoring (ABPM).7 The utility of PP has its limitations, however, 
including its propensity to increase or decrease in an individual while 
not reflecting absolute blood pressure levels.8 To account for this, 
Peng-Lin and Yue-Chun proposed a new parameter: pulse pressure 
index (PPi) (calculated as (SBP – DBP)/SBP), as a more accurate indi-
rect measure of vascular compliance.6 Its structure is similar to the 
fluid-flow analog presented by Ohm's law (pressure gradient = vol-
ume flow rate × resistance).8 Thus, PPi accounts for absolute blood 
pressure changes and is superior to PP alone as an indication of vas-
cular compliance and may potentially be a better predictor of CV 
outcomes.8
Persistent low-grade inflammation is a hallmark of CKD, and 
increased inflammation is a risk factor for CKD morbidity and 
mortality in adults.9-12 Various immunological biomarkers, includ-
ing interleukin-1 (IL-1), IL-1 receptor antagonist (IL-1RA), interleu-
kin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), tumor necrosis 
factor-beta (TNF-β), high-sensitivity C-reactive protein (hs-CRP), 
fibrinogen, and serum albumin, have been implicated in CKD 
progression.12-14 However, their role in CKD in children has not 
been established.
The value of establishing noninvasive prognostic markers for 
CVD morbidity/mortality as well as loss of kidney function is in-
tegral to improving the care of pediatric CKD population as these 
patients have yet to develop the hard end points of ESRD, heart fail-
ure, myocardial infarction, or stroke. Children are thus a population 
with the greatest potential for preventative care and improvement 
in long-term outcomes and are deserving of increased research. This 
study aims to investigate the relationship of PP, PPi, AASI, and pro-
teinuria with kidney function using the Chronic Kidney Disease in 
Children (CKiD) database from the National Institute of Diabetes 
and Digestive Kidney Diseases (NIDDK) registry.
2  | MATERIAL AND METHODS
2.1 | Study design
This is a retrospective and a cross-sectional study of 620 pediatric 
CKD patients (age 1-16 years) from the CKiD database of the NIDDK 
registry. The correlation analysis of multiple variables present in 
CKD was retrospectively assessed while the correlation analysis of 
AASI was cross-sectional. Data in this manuscript were collected by 
the Chronic Kidney Disease in Children (CKiD) study with clinical 
coordinating centers (Principal Investigators) at Children's Mercy 
Hospital at the University of Missouri-Kansas City (Bradley Warady, 
MD), Children's Hospital of Philadelphia (Susan Furth, MD, PhD), 
Central Biochemistry Laboratory (George Schwartz, MD) at the 
University of Rochester Medical Center, and the Data Coordinating 
Center (Alvaro Muñoz, PhD and Derek Ng, PhD) at Johns Hopkins' 
Bloomberg School of Public Health. These data include renal func-
tion, measurements of CV risk factors, co-morbidities, neurocogni-
tive functions, and clinical events related to end-stage renal disease 
(ESRD) and death. Children <1-year-old were excluded from the reg-
istry as glomerular filtration rate (GFR) increases during the first year 
of life, even in the presence of renal insufficiency.
2.2 | Study population
Only patients aged 1-16 years with iohexol-based glomerular filtra-
tion rate (iGFR) <60 mL/min/1.73 m2 (n = 620) were selected for 
pulse pressure and AASI correlation analysis.
2.3 | Data collection
Data regarding demographics (age, sex, race), etiology of CKD, esti-
mated GFR (eGFR) (Schwartz formula), and use of angiotensin-con-
verting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARB) 
were recorded. Laboratory markers including serum creatinine (SCr), 
urine protein levels, and immunological markers (high-sensitive 
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C-reactive protein (hs-CRP) and serum albumin) data were also 
collected.
Blood pressure was measured via auscultation using an aneroid 
sphygmomanometer (Mabis Medic-Kit 5, Mabis Healthcare), with 
the average of three auscultatory BP measurements utilized for 
analysis; the averaged HR from these three BP measurements was 
also used. PP was calculated by subtracting DBP from SBP and PPi 
was calculated by using the formula PP/SBP. The 24-hour ambula-
tory blood pressure monitoring (ABPM) was completed utilizing a 
Spacelabs 90217 monitor (SpaceLabs Healthcare); BP was measured 
every 20 minutes during the day and night. After completion of 
the monitoring period, the monitors were processed and analyzed 
at the ABPM center (University of Texas Health Science Center at 
Houston). Requirements for analysis included that the monitor was 
worn for ≥21 hours and ≥18 hours with ≥1 successful BP measure-
ment per hour.15 The AASI was calculated from unedited recordings 
as follows: The regression of diastolic on systolic BP was estimated 
for each participant (not forcing the regression line through 0) and 
AASI = (1 − regression slope).4 Echocardiograms by M-mode and 
Doppler were performed at individual participating centers, with 
the official read and analyses performed by the Cardiovascular 
Core Imaging Research Laboratory at Cincinnati Children's Hospital 
Medical Center, to measure left ventricular mass (LVM).16 Left ven-
tricular mass index (LVMI) was then calculated by indexing the LVM 
to the height of the participant.17 ABPM, AASI, and LVMI measure-
ments were analyzed with BP and laboratory data from the most 
proximate clinic visit. Correlation analysis was also performed for 
proteinuria with SBP and DBP. For analysis, significant proteinuria 
was defined as a calculated urine protein to creatinine ratio (Up/c) 
of 0.2 < 2, while nephrotic-range proteinuria was defined as a calcu-
lated Up/c ≥ 2.0.18
2.4 | Statistical analysis
Descriptive statistics (mean, standard deviation, and percentage) 
were used to describe study population demographics, measures of 
renal function, blood pressure variables, and etiology of CKD. The 
correlation of multiple variables within the overall CKD group as well 
as between the immunological and non-immunological CKD groups 
were evaluated utilizing the Pearson's correlation and backward lo-
gistic regression analysis to adjust for any potential risk factors. t tests 
were utilized to check for significant differences in renal function 
measures, blood pressure variables, immunological biomarkers, and 
use of ACEi/ARB between immunological and non-immunological 
CKD groups. Specifically, for proteinuria analysis, linear regression 
was performed and compared to the normal range Up/c (<0.2). For 
AASI calculations, the Fisher exact test was used to test differences 
between proportions while the t tests were performed to compare 
the continuous data across the various CKD groups. Any variables of 
interest with a highly skewed distribution were log-transformed be-
fore analysis. Additionally, univariate logistic regression analysis was 
used to calculate the significance F-factors while the independently 
associated variables with each stiffness parameter were evaluated 
by multiple linear regression using an ordinary least squares model.
3  | RESULTS
Patient demographics and baseline characteristics are shown in 
Table 1. On average (mean ± standard deviation), patients were 
9.63 ± 4.34 years old and weighed 40.4 ± 22.5 kg. The majority of 
patients were male and Caucasian (59.7% and 69.03%, respectively). 
Other characteristics of the studied population are shown in Table 1. 
The most common causes of CKD were obstructive uropathies fol-
lowed by aplastic/hypoplastic/dysplastic kidneys and reflux ne-
phropathy (Table 2).
Among all patients (n = 620), 16% (99/620) had CKD due to 
immunological causes while 64% (521/620) had CKD due to 
non-immunological causes (Table 2). In comparison to the non-im-
munological group, patients with immunological CKD had signifi-
cantly higher SCr levels, SBP, DBP, and PP (Table 3). Serum albumin 
was significantly lower in the immunological than the non-immu-
nological CKD group (Table 3). In contrast, there were no signifi-
cant differences in iGFR, LVMI, PPi, or hs-CRP between the two 
TA B L E  1   Demographics and clinical characteristics at baseline
Characteristics
Mean ± SD 
(n = 620)
Age (y) 9.63 ± 4.34
Sex (male (%)) 59.7
Weight (kg) 40.4 ± 22.5
Serum creatinine (μmol/L) 50 ± 31
iGFR (mL/min/1.73 m2) 37.9 ± 12.1
LVMI 30.9 ± 9.3
SBP (mm Hg) 107.9 ± 13.5
DBP (mm Hg) 66.3 ± 11.4
PP (mm Hg) 41.7 ± 10.8
PPi 0.38 ± 0.8
ACEi/ARB (%) 50.5 (n = 313)
Race
Caucasian 69.03% (n = 428)
African American (AA) 15.16% (n = 94)
Asian 2.26% (n = 14)
American Indian 1.13% (n = 7)
Native Hawaiian 0.48% (n = 3)
Other 4.03% (n = 25)
More than one race (excluding AA) 4.52% (n = 28)
More than one race (including AA) 3.39% (n = 21)
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; DBP, diastolic blood pressure; eGFR, 
estimated glomerular filtration rate; iGFR, iohexol-based GFR; LVMI, 
left ventricular mass index; PP, pulse pressure; PPi, pulse pressure 
index; SBP, systolic blood pressure.
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groups. However, there was increased usage of ACEi/ARBs noted 
in the immunological CKD group compared to the non-immuno-
logical CKD group (Table 3).
The correlation of multiple variables was investigated for the 
overall CKD group (Table 4 and Figure 1). There was a significant 
correlation between SBP and iGFR (R2 = .033; P < .001), SBP and SCr 
(R2 = .136; P < .001), and SBP and LVMI (R2 = .013; P < .001). Similarly, 
DBP and iGFR (R2 = .013; P < .001), DBP and SCr (R2 = .061; P < .001), 
and DBP and LVMI (R2 = .005; P = .035) were significant. In addition, 
PP and SCr (R2 = .039; P < .001), PP and LVMI (R2 = .005; P = .029), 
and PP and iGFR (R2 = .017; P = .011) were significant. Finally, PPi 
and SCr (R2 = .0005; P = .265) were significant but not PPi and LVMI 
(R2 = .001; P = .437) nor PPi and iGFR (R2 = .001; P = .309). There was 
no significant correlation between proteinuria and SBP (P = .11), nor 
proteinuria and DBP (P = .38; Table 5). Nephrotic-range proteinuria 
was also not significantly correlated with SBP (P = .06). However, a 
significant correlation was found between nephrotic-range protein-
uria and DBP (P = .03).
Correlations were investigated for the immunological CKD group 
(Table 4 and Figure 2). Significant correlations were seen between 
SBP and iGFR (R2 = .058; P < .001), SBP and SCr (R2 = .150; P < .001), 
and SBP and LVMI (R2 = .104; P < .001). Similarly, DBP and iGFR 
(R2 = .070; P < .001), DBP and SCr (R2 = .103; P < .001), and DBP and 
LVMI (R2 = .04; P = .006) showed significance. In addition, PP and SCr 
(R2 = .021; P = .001), and PP and LVMI (R2 = .031; P = .016) showed 
significance. However, there was no correlation between PP and 
iGFR (R2 = .0003; P = .755). Lastly, PPi and SCr (R2 = .009; P = .033) 
and PPi and iGFR (R2 = .021; P = .011) showed significance. However, 
there was no correlation between PPi and LVMI (R2 = .003; P = .492). 
To adjust for potential risk factors, a backward logistic regression 
analysis was conducted with LVMI as the dependent variable, and 
DBP, PP, and serum albumin as independent variables (Table 6). DBP, 
PP and serum albumin were all significantly associated with LVMI 
with an odds ratio (95% Confidence Interval; p value) of 0.16 (0.05, 
0.28; P = .005), 0.20 (0.07, 0.32; P = .002), and −4.84 (−7.89, −1.78; 
P = .002), respectively. Logistic regression analysis with iGFR as the 
dependent variable, and DBP, PP, and serum albumin as indepen-
dent variables was also performed. DBP was the only statistically 
significant factor associated with iGFR with an OR of −0.27 (−0.38, 
−0.16; P < .001). Logistic regression analysis with SCr as the de-
pendent variable, and DBP, PP, and serum albumin as independent 
variables was done. For SCr, both DBP and PP were statistically sig-
nificant with an OR of 0.03 (0.03, 0.04; P < .001), and 0.02 (0.01, 
0.03; P < .001), respectively.
Correlations were also investigated for the non-immunologi-
cal CKD group (Table 4 and Figure 3). There were again significant 
correlations between SBP and iGFR (R2 = .026; P < .001), and SBP 
and SCr (R2 = .130; P < .001). However, SBP and LVMI (R2 = .003; 
P = .156) were not significant. Similarly, DBP and iGFR (R2 = .004; 
P = .03) and DBP and SCr (R2 = .049; P < .001) showed significance, 
however DBP and LVMI (R2 = .001; P = .512) were not. In addition, 
PP and SCr (R2 = .044; P < .001) and PP and iGFR (R2 = .017; P < .001) 
were significant. However, PP and LVMI (R2 = .001; P = .302) was 
not. Finally, PPi and SCr (R2 = .002; P = .065) and PPi and iGFR 
(R2 = .005; P = .018) showed significance. However, PPi and LVMI 
(R2 = .001; P = .442) were not significant. To adjust for potential risk 
factors, a backward logistic regression analysis was conducted with 
LVMI as the dependent variables and DBP, PP, and serum albumin as 
independent variables (Table 6). Serum albumin was the only statis-
tically significant factor associated with LVMI with an OR of −2.63 
(−4.41, −0.86; P = .004). Logistic regression analysis with iGFR as 
TA B L E  2   Causes of chronic kidney disease
Immunological diseases
% of patients 
(n = 99)
Hemolytic uremic syndrome 5% (n = 31)
Systemic immunological disease (including SLE) 2.74% (n = 17)
Pyelonephritis/interstitial nephritis 1.94% (n = 12)
Chronic glomerulonephritis 1.61% (n = 10)
IgA nephropathy (Berger's) 1.29% (n = 8)
Membranoproliferative glomerulonephritis type I 0.81% (n = 5)
Idiopathic crescentic glomerulonephritis 0.65% (n = 4)
Membranous nephropathy 0.48% (n = 3)
Henoch-Schönlein nephritis 0.48% (n = 3)
Membranoproliferative glomerulonephritis type 
II
0.32% (n = 2)
Other glomerular diagnosis 0.65% (n = 4)
Non-immunological diseases
% of patients 
(n = 521)
Obstructive uropathy 17.74% (n = 110)
Aplastic/hypoplastic/dysplastic kidneys 17.74% (n = 110)
Reflux nephropathy 13.71% (n = 85)
Focal segmental glomerulosclerosis 8.39% (n = 52)
Polycystic kidney disease (Autosomal recessive) 3.55% (n = 22)
Renal infarct 3.06% (n = 19)
Cystinosis 1.77% (n = 11)
Syndrome of agenesis of abdominal musculature 1.77% (n = 11)
Medullary cystic disease/juvenile 
nephronophthisis
1.61% (n = 10)
Familial nephritis (Alport's) 1.45% (n = 9)
Methylmalonic acidemia 0.97% (n = 6)
Congenital urologic disease (bilateral 
hydronephrosis)
0.81% (n = 5)
Perinatal asphyxia 0.65% (n = 4)
Congenital nephrotic syndrome 0.48% (n = 3)
Wilms' tumor 0.48% (n = 3)
Polycystic kidney disease (Autosomal dominant) 0.48% (n = 3)
Sickle cell nephropathy 0.16% (n = 1)
Oxalosis 0.16% (n = 1)
Branchio-oto-renal disease/syndrome 0.16% (n = 1)
Other non-glomerular diagnosis 8.87% (n = 55)
Abbreviations: I, immunological; IgA, immunoglobin A; N, 
non-immunological.
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the dependent variable, and DBP, PP, and serum albumin as inde-
pendent variables showed that DBP, PP, and serum albumin were all 
significantly associated with an OR of −0.10 (−0.16, −0.04; P = .002), 
−0.17 (−0.24, −0.11; P < .001) and 3.95 (2.16, 5.74; P < .001), respec-
tively. Lastly, logistic regression analysis with SCr as the dependent 
variable, and DBP, PP, and serum albumin as independent variables 
was performed. DBP, PP and serum albumin were all significantly 
associated with an OR of 0.03 (0.02, 0.03; P < .001), 0.03 (0.03, 0.04; 
P < .001), and −0.25 (−0.38, −0.12; P < .001), respectively.
Ambulatory arterial stiffness index data were evaluated for cor-
relations with SBP, DBP, PP, PPi, iGFR, and LVMI. The data are only 
presented for the overall CKD population as there was no statisti-
cally significant difference between the immunological and non-im-
munological group (Table 4). When analyzing the correlation for all 
six variables with AASI, only DBP (R2 = .001; P < .001), PP (R2 = .024; 
P < .001), and PPi (R2 = .021; P < .001) showed significant correlation 
with AASI. AASI did not correlate with iGFR (R2 = .004; P < .001), 
SBP (R2 = .001; P < .001), or LVMI (R2 = .002; P < .001).
4  | DISCUSSION
Assessment of vascular compliance and function in pediatric CKD 
populations is integral to the identification and stratification of 
CVD risk factors necessary for further development of treatment 
and preventative care strategies aimed at ameliorating long-term 
morbidity and mortality. Currently, arterial assessments can utilize 
multiple modalities including Doppler ultrasound, applanation to-
nometry, oscillometer, and magnetic resonance imaging. However, 
these modalities are often difficult to incorporate in clinical prac-
tice due to the need for specialized equipment.19,20 Furthermore, 
interval references for each of these measurements by sex and/
or body size have not been well defined in the pediatric popula-
tion. This is the first study to provide analysis of markers of arterial 
compliance, including PP, PPi, and AASI, in a pediatric CKD cohort. 
The authors identified an inverse relationship between increased 
SBP, DBP, and PP with GFR and LVMI, similar to adult CKD cohorts. 
The study also evaluates these factors based on CKD etiology as 
immunological vs non-immunological. Investigations to clarify 
which modality or markers are best for CVD risk stratification may 
perhaps be best carried out in a cohort of CKD children who have 
developed “hard outcomes,” such as ESRD; thus, our findings are 
hypothesis-generating and can serve as an informative preliminary 
arbiter of risk discrimination.
TA B L E  3   Comparison of clinical parameters between patients of CKD due to immunological and non-immunological diseases
Baseline parameters
CKD due to immunological diseases 
(n = 99)
CKD due to non-immunological diseases 
(n = 521) P
Serum creatinine (mg/dL) 1.60 ± 0.70 1.40 ± 0.67 .0069
iGFR (mL/min/1.73 m2) 39.65 ± 11.09 40.76 ± 10.98 .3561
LVMI 31.59 ± 9.59 (n = 51) 32.91 ± 9.65 (n = 317) .3648
SBP (mm Hg) 112.97 ± 12.73 105.30 ± 12.85 <.0001
DBP (mm Hg) 68.9 ± 11.71 65.15 ± 11.25 .0026
PP (mm Hg) 44.07 ± 10.88 40.12 ± 10.55 .0007
PPi 0.39 ± 0.8 0.38 ± 0.8 .9046
ACEi/ARB (%) 73.5 43.1 <.0001
Serum albumin (g/dL) 3.82 ± 0.78 4.27 ± 0.96 <.0001
hs-CRP (mg/L) 4.82 ± 21.42 (n = 70) 2.64 ± 6.82 (n = 311) .1359
Abbreviations: ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; DBP, diastolic blood pressure; hs-CRP, high-
sensitive C-reactive protein; iGFR, iohexol-based glomerular filtration rate; LVMI, left ventricular mass index; PP, pulse pressure; PPi, pulse pressure 
index; SBP, systolic blood pressure.
TA B L E  4   Pearson's correlation analysis
iGFR SCr LVMI
R2 P R2 P R2 P
All patients
SBP .033 <.001 .136 <.001 .013 <.001
DBP .013 <.001 .061 <.001 .005 <.035
PP .017 .011 .005 .029 .017 .011
PPi .001 .309 .001 .265 .001 .437
AASI .004 <.001 — — .002 <.001
Immunological CKD
SBP .058 <.001 .150 <.001 .104 <.001
DBP .070 <.001 .103 <.001 .040 .006
PP .000 .755 .021 .001 .031 .016
PPi .021 .011 .009 .033 .003 .492
Non-immunological CKD
SBP .026 <.001 .130 <.001 .003 .156
DBP .004 .030 .049 <.001 .001 .512
PP .017 <.001 .044 <.001 .001 .302
PPi .005 .018 .002 .065 .001 .442
Abbreviations: DBP, diastolic blood pressure; iGFR, iohexol-based 
glomerular filtration rate; LVMI, left ventricular mass index; PP, pulse 
pressure; PPi, pulse pressure index; SBP, systolic blood pressure; SCr, 
serum creatinine.
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Pulse pressure is mainly determined by the direct force of ven-
tricular ejection and the viscoelasticity of large arteries, and in-
directly by wave reflections.21 Wave reflection is formed when 
forward-moving blood is partially reflected back from areas with 
transition in arterial impedance, for example, arterial bifurcations, 
stenoses, and peripheral beds. Increased arterial stiffness causes 
the vessel's wave reflection to become larger and arrive earlier in 
systole, thus greatly increasing PP.3 Endothelial stress and arterio-
sclerosis increase PP as loss of vascular compliance increases SBP 
while simultaneously decreasing DBP.3 Arteriosclerosis in CKD and 
ESRD patients increases arterial stiffness driving hypertension and 
increases PP. Elevated PP has previously been associated with ad-
verse cardiovascular outcomes, death, and dialysis in adult patients 
with CKD stages 4 and 5.22 Our study is the first to investigate this 
relationship in a pediatric population and demonstrate a significant 
correlation between increased PP and decreased kidney function in 
all three groups of pediatric CKD patients (Figure 1).
Pulse pressure index is significantly associated with athero-
sclerosis, CV morbidity, and CKD in adults; these are likely due to 
PPi's negative correlation with vascular compliance.20,23,24 PPi is 
also associated with increased left ventricular filling pressure and 
left ventricular diastolic dysfunction, which are common in adult 
CKD patients, especially those in pre-dialysis.7 In our overall pedi-
atric CKD group, the authors found that PP had significant associa-
tions with iGFR, SCr, and LVMI; however, PPi was not significantly 
F I G U R E  1   Significant correlations within the overall CKD group. SBP association with iGFR (A), SCr (B), and LVMI (C). DBP association 
with iGFR (D), SCr (E), and LVMI (F). PP correlation with iGFR (G), SCr (H), and LVMI (I). PPi correlation with SCr (J). iGFR, iohexol glomerular 
filtration rate; LMVI, left ventricular mass index; SBP, systolic blood pressure











60% 67% 60% .11
Nephrotic 
(Up/c > 2)




62% 67% 54% .38
Nephrotic 
(Up/c > 2)
2% 13% 23% .03
Note: The P value evaluated the linear trends across the three blood 
pressure levels and were compared to the normal Up/c range of <.2.
Abbreviations: DBP, diastolic blood pressure; SBP, systolic blood 
pressure; Up/c, urine protein to creatinine ratio.
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associated with any of the variables. Among the immunological 
CKD group, SCr significantly associated with both PP and PPi, iGFR 
correlated with PPi, and LVMI correlated only with PP. Among the 
non-immunological group, PP and PPi were significantly correlated 
with both iGFR and SCr but not LVMI. Additionally, AASI only sig-
nificantly associated with PP, PPi, and DBP. The mechanism behind 
the variability of these associations is unclear; however, the finding 
that SBP and DBP always correlate with iGFR and SCr while PP and 
PPi do so only occasionally may be indicative of the overall vascular 
compliance of our young population. The loss of vascular compli-
ance is a common end point of CKD and ESRD; however, the amount 
of time a patient has suffered from advanced CKD, as well as the 
presence of inflammation due to their disease, may be an import-
ant prognostic indicator for loss of vascular compliance in children. 
Additionally, proteinuria is also strongly associated with CKD pro-
gression and cardiovascular outcomes in adults. In our study, ne-
phrotic-range proteinuria with Up/c ≥ 2 was significantly associated 
with hypertensive range DBP. In regard to SBP, there was a trend 
toward an association with proteinuria, though it was non-signifi-
cant. In general, proteinuria has been shown to accompany various 
types of hypertensive renal diseases in pediatric patients, such as 
glomerulonephritis.
Ambulatory arterial stiffness index has been established as an 
effective predictor of arterial stiffness in the general adult popula-
tion as well as CKD patients; however, AASI has not been evaluated 
in a pediatric CKD population. Among adult hemodialysis patients, 
those with increased arterial stiffness have significantly increased 
risk of all-cause and cardiovascular mortality, and increased AASI 
also associates with early signs of renal damage in adults with pri-
mary hypertension.25 In a retrospective analysis of 418 untreated 
hypertensive patients, PP was identified as a crucial parameter for 
arterial stiffness and strong independent predictor of increasing 
AASI.26 The authors found a significant association of AASI with 
three of our six variables of interest including PP, PPi, and DBP. The 
association of AASI with established markers of vascular compli-
ance such as PP was not unexpected. However, the authors found 
that AASI correlated with DBP but not SBP. This is consistent with 
findings by Franklin et al that predictors of CVD gradually shift 
from DBP to SBP and then to PP with increasing age; specifically, 
in patients <50 years of age, DBP was the strongest predictor of 
CVD.21 This gradual age-based change is the result of how car-
diac afterload is affected by arterial stiffening. Peak SBP in the 
ascending aorta is affected by peripheral SBP distortion second-
ary to wave reflection in older individuals. In young hypertensives 
F I G U R E  2   Significant correlation within the immunological CKD group. SBP association with iGFR (A), SCr (B), and LVMI (C). DBP 
association with iGFR (D), SCr (E), and LVMI (F). PP correlation with SCr (G), and LVMI (H). PPi correlation with iGFR (I) and SCr (J). iGFR, 
iohexol glomerular filtration rate; LMVI, left ventricular mass index; SBP, systolic blood pressure
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patients, reduced peripheral amplification of SBP due to altered 
wave reflection leads a greater peripheral increase in DBP than in 
SBP while there is a parallel rise in both central SBP and DBP. Thus, 
in young individuals, elevated peripheral DBP is superior in pre-
dicting CVD.21,27 However, this finding will need to be replicated 
in a prospectively analyzed pediatric CKD population, and more 
observations are necessary in order to truly elucidate AASI's as-
sociations with CVD and long-term cardiovascular morbidity in our 
specific population.
LVH is the strongest risk factor for CVD in hypertensive popu-
lations. LVH is common among adult CKD patients and also occurs 
in 17%-49% of children with CKD.28,29 Reduction of LVM correlates 
with decreased CV events and mortality in adult hypertensive pa-
tients as well as in CKD stage 5 patients on renal replacement ther-
apy.28,29 Common risk factors for LVH in CKD include anemia, fluid 
overload, and hypertension.28 In our cohort, SBP and DBP signifi-
cantly correlated with LVMI in the overall CKD group and immuno-
logical CKD group. However, LVMI did not correlate with SBP nor 
DBP in the non-immunological group. This finding is consistent with 
adult CKD data that immunological markers such as CRP, interleu-
kin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) are LVH 
risk factors.30 Furthermore, inflammation is also highly prevalent in 
pre-dialysis CKD patients and immunological markers are associated 
with increased LVMI in adult CKD patients.31,32
Studies have established the association of low-grade chronic 
inflammation and immunological markers with progression of CKD 
and all-cause mortality.9,12 The underlying mechanisms of chronic 
low-grade inflammation in CKD include increased production and 
reduced clearance of pro-immunomodulatory cytokines, oxidative 
stress, acidosis, chronic or recurrent infections, altered metabolism 
of adipose tissue, and intestinal dysbiosis.10,33 Various immunolog-
ical biomarkers, including IL-1, IL-6, TNF-alpha, TNF-beta, hs-CRP, 
fibrinogen, and serum albumin, have been implicated in the progres-
sion of CKD.12 Furthermore, increased levels of immunological mark-
ers (fibrinogen and TNF-alpha) and reduced levels of serum albumin 
are associated with rapid loss of renal functions in pediatric CKD 
patients.12 However, the exact mechanism by which inflammation 
contributes to CKD progression is unknown.10 While our study did 
include the immunological marker hs-CRP, the authors did not find 
a significant difference in hs-CRP levels between patients with im-
munological and non-immunological CKD. However, the authors did 
demonstrate that serum albumin was significantly lower in the im-
munological than the non-immunological CKD group. Unfortunately, 
the relationship between hs-CRP, serum albumin, and iGFR could 
not be established due to variation in data collection time points.
Inflammation has been linked to elevated blood pressure and 
cardiovascular morbidity and mortality.34,35 Approximately 50% of 
CKD patients have increased mortality due to CV complications, 
such as advanced calcific arterial and valvular disease, which 
has been linked to chronic inflammation.36 Probable underlying 
pathogenesis includes an imbalance between vasoconstrictors 
and vasodilators, increased thrombogenesis, platelet activation, 
and the direct effect of immunological mediators.35 Increased lev-
els of CRP, IL-6, and leukocyte adhesion molecules were shown 
to predict the risk of CV events.13 Our study showed significant 
elevations in SBP, DBP, and PP in the immunological CKD group 
(Figure 2) compared to the non-immunological group (Figure 3). 
In addition, both PP and DBP were significantly associated with 
LVMI on regression analysis for the immunological CKD group but 
not the non-immunological group. ACEi/ARBs were significantly 
higher among the immunological CKD group implying higher blood 
pressures among these patients (Table 3). In the future, prospec-
tive studies should be conducted in order to further corroborate 
the results shown.
5  | CONCLUSIONS
This study is one of the first to assess a pediatric CKD cohort using 
noninvasive surrogate markers of arterial stiffness. The authors have 
demonstrated an inverse relationship between SBP, DBP, and PP 
with decreased GFR and elevated LVMI in children, similar to adults. 
In addition, the authors have demonstrated differences in these re-
lationships by CKD etiology as immunological or non-immunological, 
which is unique and hypothesis-generating. Our immunological CKD 
TA B L E  6   Backward logistic regression analysis for 









DBP 0.16 0.28 0.05 .005
PP 0.20 0.32 0.07 .002
Serum albumin −4.84 −1.78 −7.89 .002
iGFR
DBP 0.27 −0.16 −0.38 <.001
SCr
DBP 0.03 0.04 0.03 <.001
PP 0.02 0.03 0.01 <.001
Non-Immunological CKD
LVMI
SBP −2.63 −0.86 −4.41 .004
iGFR
DBP −0.10 −0.04 −0.16 .002
PP −0.17 −0.11 −0.24 <.001
Serum albumin 3.95 5.74 2.16 <.001
SCr
DBP 0.03 0.03 0.02 <.001
PP 0.03 0.04 0.03 <.001
Serum albumin −0.25 −0.12 −0.38 <.001
Abbreviations: DBP, diastolic blood pressure; iGFR, iohexol-based 
glomerular filtration rate; LVMI, left ventricular mass index; PP, pulse 
pressure; SCr, serum creatinine.
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subgroup children showed significantly higher SCr, SBP, DBP, PP and 
significantly lower serum albumin levels. Subgroup analysis of CKD 
patients demonstrated that SBP, DBP, and PP were all significantly 
correlated with LVMI in immunological CKD patients but not non-
immunological. These findings suggest that effective blood pressure 
control is of paramount importance in children with CKD due to im-
munological causes to decrease their long-term CV morbidity.
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